ADC-1

N/A

Report date: 2025/03/27 13:19:57

Base Information

Drug NameADC-1

Drug Alias NameRC58-based ADCADC-1

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > Maleimide PEG linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PNU-159682 payload

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLeukemia, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesJiangsu Pacific Minok Biopharmaceutical Co., Ltd.

China Registration ClassN/A

Develop Information

Active CompaniesRemeGen Co Ltd

Inactive CompaniesN/A

Active IndicationsLeukemia, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A